MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Marker Therapeutics Announces $16.1 Million Private Placement
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
Why Is Marker Therapeutics (MRKR) Stock Up 27% Today?
7 Low Float Penny Stocks To Watch After SNTG Stock Explodes
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
3 Hot Penny Stocks To Buy For Under $1 Right Now
Marker Therapeutics to Present at Two Upcoming March Investor Conferences